Literature DB >> 18321666

Evaluation of neonatal BH4 loading test in neonates screened for hyperphenylalaninemia.

François Feillet1, Céline Chery, Fares Namour, Antoine Kimmoun, Elisabeth Favre, Elisabeth Lorentz, Shyue-Fang Battaglia-Hsu, Jean-Louis Guéant.   

Abstract

BACKGROUND: The outcome in phenylketonuria is related to the early diagnosis and management due to neonatal screening. AIMS: To assess the interest of tetrahydrobiopterin (BH4) loading test and phenylalanine hydroxylase (PAH) genotyping in the management of neonates with hyperphenylalaninemia (HPA). STUDY
DESIGN: We evaluate the effectiveness of a BH4 loading test (20 mg/kg) in ten neonates screened for HPA. We evaluated the time required to reach a target plasma Phenylalanine (Phe) level below 300 micromol/l. We compared these ten BH4-loaded patients to the 10 previous neonates non-loaded with BH4. In all these patients, the PAH genotype was determined.
RESULTS: One loaded patient had biopterin synthesis deficiency and has been retrieved from statistical analysis. All others patients have PAH deficiency. Between the BH4 loaded group (L) and the BH4 non-loaded group (NL), a statistically significant difference was observed in the average time required to reached the target Phe level (13.56 +/- 4.30 (L) vs. 20.6 +/- 7.59 days (NL) [p < 0.02]). Results of the genotyping from all but one of these 19 patients indicated that among all mutations present in this patient population, there were 4 known PAH mutations associated with BH4 responsiveness (p.R261Q, the p.V388 M, the p.E390G and the p.Y414C). These mutations were found in 4 non-loaded and 6 loaded patients. Two patients had a more than 90% reduction in their plasma Phe level within 24 h after the load. One of these patients had a PTPS deficiency. The other fully responsive patient (p.Y414C and IVS10-11G>A) has been treated with BH4 from birth with an excellent metabolic control for three years now.
CONCLUSION: BH4 loading test improves the management of HPA. It allows an immediate identification of the children fully responsive to BH4. Our results therefore suggest the incorporation of BH4 loading test in the management of neonates screened for HPA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18321666     DOI: 10.1016/j.earlhumdev.2008.01.003

Source DB:  PubMed          Journal:  Early Hum Dev        ISSN: 0378-3782            Impact factor:   2.079


  5 in total

1.  Long-term pharmacological management of phenylketonuria, including patients below the age of 4 years.

Authors:  M L Couce; M D Bóveda; E Valerio; A Pérez-Muñuzuri; J M Fraga
Journal:  JIMD Rep       Date:  2011-09-06

2.  Efficacy and safety of BH4 before the age of 4 years in patients with mild phenylketonuria.

Authors:  Oriane Leuret; Magalie Barth; Alice Kuster; Didier Eyer; Loïc de Parscau; Sylvie Odent; Brigitte Gilbert-Dussardier; François Feillet; François Labarthe
Journal:  J Inherit Metab Dis       Date:  2012-03-03       Impact factor: 4.982

3.  Sapropterin hydrochloride: enzyme enhancement therapy for phenylketonuria.

Authors:  Robin Lachmann
Journal:  Ther Adv Endocrinol Metab       Date:  2011-06       Impact factor: 3.565

Review 4.  Up to date knowledge on different treatment strategies for phenylketonuria.

Authors:  Amaya Bélanger-Quintana; Alberto Burlina; Cary O Harding; Ania C Muntau
Journal:  Mol Genet Metab       Date:  2011-08-16       Impact factor: 4.797

5.  The neonatal tetrahydrobiopterin loading test in phenylketonuria: what is the predictive value?

Authors:  Karen Anjema; Floris C Hofstede; Annet M Bosch; M Estela Rubio-Gozalbo; Maaike C de Vries; Carolien C A Boelen; Margreet van Rijn; Francjan J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2016-01-29       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.